Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KA-1769
- Development stage
- Preclinical
- Lead developer
- KYINNO BIOTECHNOLOGY
- Modality
- Antibody-Based Therapeutics
01
Overview
KA-1769: sourced facts only. name: "Here we developed a LILRB2 antagonist antibody KA-1769 for reprogramming M2 macrophage to M1 phenotype." [DOI:10.1158/1538-7445.am2023-592]; target: "Here we developed a LILRB2 antagonist antibody KA-1769 for reprogramming M2 macrophage to M1 phenotype." [DOI:10.1158/1538-7445.am2023-592]; developer: "1Kyinno Biotechnology Co., Ltd, Beijing, China." [DOI:10.1158/1538-7445.am2023-592]; modality: "Here we developed a LILRB2 antagonist antibody KA-1769 for reprogramming M2 macrophage to M1 phenotype." [DOI:10.1158/1538-7445.am2023-592]; stage: "In a syngeneic Lewis lung carcinoma murine model with LILRB2-transgenic mice, injection of KA-1769 significantly suppressed tumor growth." [DOI:10.1158/1538-7445.am2023-592]
02
Targets
LILRB2 (Leukocyte immunoglobulin-like receptor subfamily B member 2)
Beyond the preview
Go deeper on KA-1769.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KA-1769.